NEUROCHEMISTRY INTERNATIONAL, published by Pergamon-Elsevier Science Ltd, offers a premier platform for researchers and professionals in the realms of cell biology and cellular and molecular neuroscience. Established in 1980 and continuing its passion for advancing the field, this esteemed journal enhances scientific collaboration with a notable 2023 Q2 ranking in both relevant categories, placing it among the top-tier publications in its discipline with a Scopus rank of 23/97 for Cellular and Molecular Neuroscience. With its focus on groundbreaking research, the journal provides a wealth of vital data and insights that drive forward our understanding of neurochemistry and its implications in health and disease. While not an Open Access journal, NEUROCHEMISTRY INTERNATIONAL is integral for professionals, academics, and students aiming to stay at the forefront of neurobiological research innovations, making significant contributions to both academia and clinical applications.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

NEUROBIOLOGY OF DISEASE is a premier journal dedicated to advancing the understanding of neurological disorders and the underlying biological processes, published by Academic Press Inc, Elsevier Science. With an impressive impact factor indicative of its significance—ranked in the Q1 quartile in Neurology for 2023 and occupying the 14th rank out of 192 journals in the field of Neuroscience and Neurology—this journal serves as a critical resource for researchers, clinicians, and students alike. The journal has a rich history since its inception in 1994, continuously evolving its scope to encompass groundbreaking research and insights into neurobiological mechanisms and disease pathology. Though it currently does not provide Open Access options, NEUROBIOLOGY OF DISEASE remains a vital vessel for disseminating knowledge that significantly contributes to the field of neurology, fostering an understanding that can lead to innovative therapeutic strategies.

The Journal of Huntington's Disease is a premier academic publication dedicated to advancing the understanding of Huntington's disease and related neurodegenerative disorders. Published by IOS PRESS, this journal has established itself as a vital resource for the scientific community, with an impressive impact factor reflecting its rigorous standards and influential research contributions. With a converged publication period from 2012 to 2024, the journal holds esteemed rankings in the 2023 Q2 category for Cellular and Molecular Neuroscience and Q1 for Neurology (clinical) on Scopus, highlighting its relevance and authority within these critical fields. Researchers, professionals, and students will find a wealth of peer-reviewed articles that examine the molecular mechanisms, clinical manifestations, and therapeutic strategies related to Huntington’s disease. Although not an open-access journal, it provides various access options to ensure that critical research reaches its intended audience. As an essential platform for disseminating groundbreaking findings in neurology and neuroscience, the Journal of Huntington's Disease plays a crucial role in shaping the future of research and treatment strategies related to this devastating condition.

Annals of Indian Academy of Neurology is a premier open access journal dedicated to advancing the field of Neurology, serving as a vital resource for researchers, healthcare professionals, and students since its inception in 2006. Published by the esteemed Wolters Kluwer Medknow Publications, this journal has established itself within the academic community, boasting a Q3 quartile ranking in clinical neurology according to the 2023 category quartiles and a Scopus rank placing it in the 35th percentile among 400 comparable journals. With a focus on clinical advancements and research innovations in neurology, the journal aims to disseminate high-quality and impactful studies that address the complex challenges faced in the neurological landscape, particularly within the Indian context. The open access model ensures that the latest research is readily accessible to a global audience, thereby promoting collaboration and knowledge sharing within the neurosciences.

CURRENT OPINION IN NEUROLOGY is a premier academic journal dedicated to providing insightful overviews and critical analyses across all areas of neurology and clinical neurology. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an impressive impact factor, highlighting its influence and relevance in the field—positioning it in the Q1 category for both neurology and clinical neurology as of 2023. With its comprehensive coverage, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to stay abreast of the latest developments, trends, and breakthroughs in neurological science and practice. Though not open access, articles are available via institutional subscriptions or individual purchase, ensuring that vital research remains accessible to a wide audience. Covering research from its inception in 1993 to ongoing studies in 2024, CURRENT OPINION IN NEUROLOGY stands out as an essential platform for disseminating knowledge and fostering dialogue within the dynamic and evolving landscape of neurology.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

Alzheimers & Dementia is a premier journal published by WILEY that focuses on the latest advancements in understanding, diagnosing, and treating Alzheimer's disease and other dementias. With an ISSN of 1552-5260 and an E-ISSN of 1552-5279, this influential journal boasts a commendable impact factor and ranks in the Q1 category across several disciplines, including *Cellular and Molecular Neuroscience*, *Geriatrics and Gerontology*, and *Neurology (Clinical)*. By publishing cutting-edge research, systematic reviews, and innovative clinical trials, Alzheimers & Dementia aims to bridge the gap between basic neuroscience and clinical practice, offering valuable insights into the etiology, epidemiology, and management of dementia-related disorders. The journal is hosted in the United States and operates under a balanced access model, providing essential resources for researchers, healthcare professionals, and students dedicated to tackling the challenges posed by these neurodegenerative diseases. Available online, it plays a pivotal role in shaping current and future research directions in the vibrant field of dementia studies.

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

Aging-US is a premier peer-reviewed journal dedicated to advancing the field of aging research and cell biology. Published by IMPACT JOURNALS LLC, this journal serves as a vital resource for researchers and professionals exploring the biological mechanisms of aging and their implications for health and disease. With a commendable impact factor reflected in its 2023 Scopus rankings, where it stands at Rank #10/38 in the category of Aging and Rank #63/285 in Cell Biology, Aging-US exemplifies rigorous scientific excellence. Its open access policy enhances accessibility, fostering a wider dissemination of knowledge in both academic and clinical settings. Spanning from 2009 to 2024, the journal provides a platform for groundbreaking studies and innovative methodologies, ensuring that it remains at the forefront of the dynamic conversations surrounding aging and cellular biology. Engage with Aging-US to contribute to the evolving narratives of longevity and cellular health.